ARTICLE SUMMARY:
Stanley Rose, a serial biotech entrepreneur, formed Transplant Genomics Inc. in 2013 to apply recent advances in genomic biomarkers to the field of transplant medicine. The company aims to fill an acute unmet need for precise monitoring tools that can noninvasively assess the health of a transplanted organ.
When Stanley Rose, PhD, a serial biotech entrepreneur, biologist, and recent kidney transplant recipient, read an article in the December 2012 issue of Clinical Laboratory News, he was struck by the survey of burgeoning research on applying genomics to improve current, relatively primitive methods for monitoring organ transplant recipients. He decided to form Transplant Genomics Inc. (TGI) to capitalize on the most promising approaches to addressing the huge unmet need.
